The Role of Sulodexide in the Treatment of Diabetic Nephropathy

Overview

Journal Drugs

Specialty Pharmacology

Date 2007 Dec 8

PMID 18062718

Citations 16

Authors

Ram Weiss

Robert Niecestro

Itamar Raz

Affiliations

Soon will be listed here.

Abstract

Diabetic nephropathy is an important cause of morbidity and mortality in patients with either type 1 or type 2 diabetes mellitus. The pathogenesis and natural history of diabetic nephropathy, characterised by a progressive decline in glomerular function, were initially described in patients with type 1 diabetes. Reports that describe the glomerulopathy and progression of renal disease in patients with type 2 diabetes suggest that the disease process is similar to that observed in patients with type 1 diabetes with diabetic nephropathy. An emerging body of evidence supports the notion that glomerular capillary wall and mesangial alterations in diabetic nephropathy involve pathobiochemical alterations of glycoproteins in these structures. Evidence in experimental animals rendered diabetic, reveal that the administration of heparin and other anionic glycoproteins can effectively prevent the biochemical alterations that promote albuminuria. Clinical reports of the use of sulodexide, a preparation of low molecular weight glycosaminoglycan polysaccharides, have shown that proteinuria is significantly diminished in patients with diabetic nephropathy, even when these patients are receiving either an ACE inhibitor or angiotensin receptor antagonist.

Citing Articles

Endothelial Dysfunction in Patients Undergoing Cardiac Surgery: A Narrative Review and Clinical Implications.

Knezevic D, Curko-Cofek B, Batinac T, Laskarin G, Rakic M, Sostaric M J Cardiovasc Dev Dis. 2023; 10(5).

PMID: 37233179 PMC: 10218891. DOI: 10.3390/jcdd10050213.

Sulodexide Prevents Hyperglycemia-Induced Endothelial Dysfunction and Oxidative Stress in Porcine Retinal Arterioles.

Dauth A, Breborowicz A, Ruan Y, Tang Q, Zadeh J, Bohm E Antioxidants (Basel). 2023; 12(2).

PMID: 36829947 PMC: 9952154. DOI: 10.3390/antiox12020388.

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis.

Bignamini A, Chebil A, Gambaro G, Matuska J Adv Ther. 2021; 38(3):1483-1513.

PMID: 33502688 PMC: 7932977. DOI: 10.1007/s12325-021-01620-1.

Sulodexide attenuates endoplasmic reticulum stress induced by myocardial ischaemia/reperfusion by activating the PI3K/Akt pathway.

Shen D, Chen R, Zhang L, Rao Z, Ruan Y, Li L J Cell Mol Med. 2019; 23(8):5063-5075.

PMID: 31120192 PMC: 6653332. DOI: 10.1111/jcmm.14367.

Improvements in the Management of Diabetic Nephropathy.

Dounousi E, Duni A, Leivaditis K, Vaios V, Eleftheriadis T, Liakopoulos V Rev Diabet Stud. 2015; 12(1-2):119-33.

PMID: 26676665 PMC: 5397987. DOI: 10.1900/RDS.2015.12.119.

References

Cristofori M, Mastacchi R, Barbanti M, Sarret M . Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats. Arzneimittelforschung. 1985; 35(10):1513-6. View

Lambers Heerspink H, Fowler M, Volgi J, Reutens A, Klein I, Herskovits T . Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med. 2007; 24(11):1290-5. DOI: 10.1111/j.1464-5491.2007.02249.x. View

Caenazzo C, Garbisa S, Onisto M, Zampieri M, Baggio B, Gambaro G . Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Nephrol Dial Transplant. 1997; 12(3):443-8. DOI: 10.1093/ndt/12.3.443. View

Matsumoto T, Yamaguchi M, Kikuchi H, Nakano H, Midorikawa T, Kumada K . Heparin reduces serum levels of endothelin-1 and hepatic ischemia reperfusion injury in rabbits. Surg Today. 2000; 30(6):523-5. DOI: 10.1007/s005950070119. View

Rossing P, Hommel E, Smidt U, Parving H . Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl. 1994; 45:S145-9. View

Wang Z, Liang K, Pahl M, Vaziri N . Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Nephrol Dial Transplant. 1998; 13(12):3052-7. DOI: 10.1093/ndt/13.12.3052. View

Oksa A, Pontuch P, Kratochvilova H . [The effect of glycosaminoglycan sulodexide on albuminuria in patients with diabetes mellitus]. Bratisl Lek Listy. 2000; 100(9):486-9. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Sorrenti G, Grimaldi M, Canova N, Palazzini E, Melchionda N . Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997; 25(2):81-6. DOI: 10.1177/030006059702500204. View

10.

van den Hoven M, Rops A, Bakker M, Aten J, Rutjes N, Roestenberg P . Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006; 70(12):2100-8. DOI: 10.1038/sj.ki.5001985. View

11.

Ruggenenti P, Gambara V, Perna A, Bertani T, Remuzzi G . The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol. 1998; 9(12):2336-43. DOI: 10.1681/ASN.V9122336. View

12.

Crepaldi G, Fellin R, Calabro A, Baiocchi M, Rossi A, Lenzi S . Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial. Monogr Atheroscler. 1986; 14:215-21. View

13.

Condorelli M, Chiariello M, DAGIANTI A, Penco M, DALLA VOLTA S, Pengo V . IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994; 23(1):27-34. DOI: 10.1016/0735-1097(94)90498-7. View

14.

Inomata S, Nakamoto Y, Inoue M, Itoh M, Ohsawa Y, Masamune O . Relationship between urinary albumin excretion rate and renal histology in non-insulin-dependent diabetes mellitus: with reference to the clinical significance of microalbuminuria. J Diabet Complications. 1989; 3(3):172-8. DOI: 10.1016/0891-6632(89)90042-1. View

15.

Dedov I, Shestakova M, Vorontzov A, Palazzini E . A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997; 12(11):2295-300. DOI: 10.1093/ndt/12.11.2295. View

16.

Ruggenenti P, Remuzzi G . Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol. 1998; 9(11):2157-69. DOI: 10.1681/ASN.V9112157. View

17.

Wight J, Edwards L, Brazier J, Walters S, Payne J, Brown C . The SF36 as an outcome measure of services for end stage renal failure. Qual Health Care. 1999; 7(4):209-21. PMC: 2483621. DOI: 10.1136/qshc.7.4.209. View

18.

Gambaro G, Kinalska I, Oksa A, Pontuch P, Hertlova M, Olsovsky J . Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002; 13(6):1615-25. DOI: 10.1097/01.asn.0000014254.87188.e5. View

19.

Ruggeri A, Guizzardi S, Franchi M, Morocutti M, Mastacchi R . Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35(10):1517-9. View

20.

Ishikawa Y, Kitamura M . Inhibition of glomerular cell apoptosis by heparin. Kidney Int. 1999; 56(3):954-63. DOI: 10.1046/j.1523-1755.1999.00639.x. View